LSBCF (LakeShore Biopharma Co) Total Liabilities: $119.72 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Total Liabilities?

LakeShore Biopharma Co LSBCF Total Liabilities is $119.72 Mil as of Mar. 2025. The stock has 5 warning signs investors should review.

LakeShore Biopharma Co's Total Liabilities for the quarter that ended in Mar. 2025 was $119.72 Mil.

LakeShore Biopharma Co's quarterly Total Liabilities declined from Mar. 2024 ($128.84 Mil) to Sep. 2024 ($117.31 Mil) but then increased from Sep. 2024 ($117.31 Mil) to Mar. 2025 ($119.72 Mil).

LakeShore Biopharma Co's annual Total Liabilities declined from Mar. 2023 ($143.86 Mil) to Mar. 2024 ($128.84 Mil) and declined from Mar. 2024 ($128.84 Mil) to Mar. 2025 ($119.72 Mil).

LakeShore Biopharma Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Total Liabilities Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
257.42 337.41 143.86 128.84 119.72

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only 143.86 144.45 128.84 117.31 119.72

LakeShore Biopharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LakeShore Biopharma Co's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=113.77+(3.242+0.475
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.236+0+0)
=119.72

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=188.661-68.938
=119.72

LakeShore Biopharma Co's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=113.77+(3.242+0.475
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.236+0+0)
=119.72

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=188.661-68.938
=119.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $119.72 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Total Liabilities of $119.72 Mil as of Mar. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Total Liabilities too high?
LakeShore Biopharma Co's current Total Liabilities is $119.72 Mil.
How does LakeShore Biopharma Co's Total Liabilities compare to ACUT and PPCB?
LakeShore Biopharma Co's Total Liabilities of $119.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Total Liabilities is $119.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Total Liabilities of $119.72 Mil. The current Total Liabilities is $119.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Total Liabilities is $119.72 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.